SAREPTA THERAP (AB3A BE) stock market data APIs
€30.7965
0(0%)
as of May 16, 2025
Try our APIs with
free plan!
SAREPTA THERAP Financial Data Overview
There is no Profile data available for AB3A.BE.
Prev. Close
30.7965
Open
30.7965
High
30.7965
Low
30.7965
52 wk Range
31.09-156
Market Cap
6 592 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SAREPTA THERAP data using free add-ons & libraries
Get SAREPTA THERAP Fundamental Data
SAREPTA THERAP Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SAREPTA THERAP News
New
Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy
Sarepta Therapeutics (SRPT) said Friday that new data from two separate studies of its gene therapy PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
- Treatment with ELEVIDYS for Duchenne muscular dystrophy resulted in mean protein expression of 93.87% as measured by western blot in study participants (n=6) - Safety profile consistent with prior ...
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
Significant functional benefits for 8- and 9-year-olds with Duchenne in Part 2 of the EMBARK study, contributing to the evidence of stabilization or slowing of disease progression in later childhood w...
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COV...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
